Triple-negative breast cancer and the potential for targeted therapy

Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer

(2017) Jonathan Rennhack et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis

(2017) J-R Jhan et al.   ONCOGENE

Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer

(2017) Kristin K. Brown et al.   Cancer Discovery

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer

(2017) Reva K. Basho et al.   JAMA Oncology

WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance

(2017) Hongping Zheng et al.   Scientific Reports

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer

(2016) Nidal E. Muvarak et al.   CANCER CELL

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition

(2016) Pau Castel et al.   CANCER CELL

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

(2016) Alejandra Bruna et al.   CELL

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

(2016) N.C. Synnott et al.   INTERNATIONAL JOURNAL OF CANCER

RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation

(2016) Robert A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

(2016) Rinske Drost et al.   JOURNAL OF CLINICAL INVESTIGATION

Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology

(2016) Eunah Shin et al.   Journal of Translational Medicine

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer

(2016) Roman Camarda et al.   NATURE MEDICINE

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

(2016) Hope S. Rugo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting WEE1 Kinase in Cancer

(2016) Christopher J. Matheson et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer

(2016) Meiou Dai et al.   Scientific Reports

Retrospective analysis of metastatic behaviour of breast cancer subtypes

(2015) C. Dilara Savci-Heijink et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting the androgen receptor in prostate and breast cancer: several new agents in development

(2015) T. Proverbs-Singh et al.   ENDOCRINE-RELATED CANCER

Will Targeting Chk1 Have a Role in the Future of Cancer Therapy?

(2015) Nandini Sakurikar et al.   JOURNAL OF CLINICAL ONCOLOGY

NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:

(2015) Caroline McNeil   JNCI-Journal of the National Cancer Institute

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel

(2015) Zhen Ning Wee et al.   Nature Communications

NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:

(2015) Caroline McNeil   JNCI-Journal of the National Cancer Institute

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells

(2014) Jian Kang et al.   BMC CANCER

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

(2014) Christopher Bryant et al.   BMC CANCER

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

(2014) Jasmeet Chadha Singh et al.   BREAST CANCER RESEARCH

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

The E2F Transcription Factors Regulate Tumor Development and Metastasis in a Mouse Model of Metastatic Breast Cancer

(2014) D. P. Hollern et al.   MOLECULAR AND CELLULAR BIOLOGY

Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance

(2014) E. Rozengurt et al.   MOLECULAR CANCER THERAPEUTICS

Clonal evolution in breast cancer revealed by single nucleus genome sequencing

(2014) Yong Wang et al.   NATURE

Wnt signaling in triple negative breast cancer is associated with metastasis

(2013) Nandini Dey et al.   BMC CANCER

A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells

(2013) Fabio Petrocca et al.   CANCER CELL

Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer

(2013) Rachel M. Layman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

(2013) I. Bajrami et al.   CANCER RESEARCH

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis

(2013) F. E. Vera-Badillo et al.   JNCI-Journal of the National Cancer Institute

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors

(2013) E R Andrechek   ONCOGENE

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

(2013) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

(2013) J. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

(2012) M. L. McCleland et al.   CANCER RESEARCH

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

(2012) Nicola Aceto et al.   NATURE MEDICINE

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

(2012) J C Montero et al.   ONCOGENE

Src: a potential target for the treatment of triple-negative breast cancer

(2011) D. Tryfonopoulos et al.   ANNALS OF ONCOLOGY

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

(2011) R. S. Finn et al.   CLINICAL CANCER RESEARCH

FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo

(2011) Rachel Sharpe et al.   CLINICAL CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer

(2011) Markus K Muellner et al.   Nature Chemical Biology

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

(2011) Yoko S DeRose et al.   NATURE MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

(2010) N Turner et al.   ONCOGENE

A pathway-based classification of human breast cancer

(2010) M. L. Gatza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential

(2009) E. R. Andrechek et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

(2009) M. G. Ponzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

(2008) E. M. Swisher et al.   CANCER RESEARCH

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA